Mouse models for LRRK2 Parkinson's disease
- PMID: 22166430
- DOI: 10.1016/S1353-8020(11)70058-X
Mouse models for LRRK2 Parkinson's disease
Abstract
Parkinson's disease (PD) is the second most common neurodegenerative disease. Mutations in Leucine-rich-repeat-kinase 2 (LRRK2), the causative gene for PARK8 type PD with autosomal dominant inheritance, are the most prevalent genetic causes of both familial and sporadic PD. Animal models are critical tools in the attempt to understand the mechanisms of LRRK2-mediated pathogenesis. We have generated human Bacterial Artificial Chromosome (BAC) mediated transgenic mouse models expressing mutant LRRK2 that robustly recapitulate the behavioral, neurochemical and pathological features of PD. These mice develop an age-dependent decrease in motor activity that is progressive and responds to treatment with levodopa. Pathologically, the most salient phenotype is early axonopathy of nigrostriatal dopaminergic neurons, accompanied by hyperphosphorylated tau. The mice also exhibit a consistent dopamine transmission deficit in both acute brain slices and live freely moving animals. Here we will discuss LRRK2 mouse models from several laboratories, their commonalities and differences, and offer scientific insights drawn from these studies.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
-
Lack of exacerbation of neurodegeneration in a double transgenic mouse model of mutant LRRK2 and tau.Hum Mol Genet. 2015 Jun 15;24(12):3545-56. doi: 10.1093/hmg/ddv105. Epub 2015 Mar 24. Hum Mol Genet. 2015. PMID: 25804954
-
The mouse/human cross-species heterodimer of leucine-rich repeat kinase 2: possible significance in the transgenic model mouse of Parkinson's disease.Neurosci Lett. 2015 Feb 19;588:142-6. doi: 10.1016/j.neulet.2015.01.003. Epub 2015 Jan 3. Neurosci Lett. 2015. PMID: 25562633
-
Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S.J Neurosci. 2010 Feb 3;30(5):1788-97. doi: 10.1523/JNEUROSCI.5604-09.2010. J Neurosci. 2010. PMID: 20130188 Free PMC article.
-
[Clinical molecular genetics for PARK8 (LRRK2)].Brain Nerve. 2007 Aug;59(8):839-50. Brain Nerve. 2007. PMID: 17713120 Review. Japanese.
-
Kinase signaling dysfunction in Parkinson's disease: a reverse genetic approach in Drosophila.J Neurogenet. 2012 Jun;26(2):158-67. doi: 10.3109/01677063.2012.672499. Epub 2012 Apr 10. J Neurogenet. 2012. PMID: 22486164 Review.
Cited by
-
LRRK2 mutant knock-in mouse models: therapeutic relevance in Parkinson's disease.Transl Neurodegener. 2022 Feb 14;11(1):10. doi: 10.1186/s40035-022-00285-2. Transl Neurodegener. 2022. PMID: 35152914 Free PMC article. Review.
-
LRRK2: cause, risk, and mechanism.J Parkinsons Dis. 2013;3(2):85-103. doi: 10.3233/JPD-130192. J Parkinsons Dis. 2013. PMID: 23938341 Free PMC article. Review.
-
Cellular effects of LRRK2 mutations.Biochem Soc Trans. 2012 Oct;40(5):1070-3. doi: 10.1042/BST20120165. Biochem Soc Trans. 2012. PMID: 22988867 Free PMC article. Review.
-
Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease.Cell Death Dis. 2018 Feb 12;9(2):204. doi: 10.1038/s41419-017-0221-2. Cell Death Dis. 2018. PMID: 29434188 Free PMC article.
-
Combined LRRK2 mutation, aging and chronic low dose oral rotenone as a model of Parkinson's disease.Sci Rep. 2017 Jan 18;7:40887. doi: 10.1038/srep40887. Sci Rep. 2017. PMID: 28098219 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical